Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 December 2007, Vol. 110, No. 13, pp. 4427-4435.
Prepublished online as a Blood First Edition Paper on September 5, 2007; DOI 10.1182/blood-2007-05-090621.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Tables and Figures
Right arrow All Versions of this Article:
blood-2007-05-090621v1
110/13/4427    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guzman, M. L.
Right arrow Articles by Jordan, C. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guzman, M. L.
Right arrow Articles by Jordan, C. T.
Related Collections
Right arrow Neoplasia
Right arrow Stem Cells in Hematology
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells

Monica L. Guzman1, Randall M. Rossi1, Sundar Neelakantan2, Xiaojie Li1, Cheryl A. Corbett1, Duane C. Hassane1, Michael W. Becker1, John M. Bennett1, Edmund Sullivan3, Joshua L. Lachowicz4, Andrew Vaughan5, Christopher J. Sweeney6, William Matthews7, Martin Carroll8, Jane L. Liesveld1, Peter A. Crooks2, and Craig T. Jordan1

1 James P. Wilmot Cancer Center, University of Rochester, NY; 2 College of Pharmacy, University of Kentucky, Lexington; 3 Advanced Veterinary Services, Bellingham, WA; 4 Redbank Veterinary Hospital, Tinton Falls, NJ; 5 Las Vegas Veterinary Referral Center, NV; 6 Department of Medicine, Indiana University School of Medicine, Indianapolis; 7 Leuchemix, Woodside, CA; and 8 Division of Hematology and Oncology, University of Pennsylvania, Philadelphia

Leukemia stem cells (LSCs) are thought to play a central role in the pathogenesis of acute leukemia and likely contribute to both disease initiation and relapse. Therefore, identification of agents that target LSCs is an important consideration for the development of new therapies. To this end, we have previously demonstrated that the naturally occurring compound parthenolide (PTL) can induce death of human LSCs in vitro while sparing normal hematopoietic cells. However, PTL has relatively poor pharmacologic properties that limit its potential clinical use. Consequently, we generated a family of PTL analogs designed to improve solubility and bioavailability. These studies identified an analog, dimethylamino-parthenolide (DMAPT), which induces rapid death of primary human LSCs from both myeloid and lymphoid leukemias, and is also highly cytotoxic to bulk leukemic cell populations. Molecular studies indicate the prevalent activities of DMAPT include induction of oxidative stress responses, inhibition of NF-{kappa}B, and activation of p53. The compound has approximately 70% oral bioavailability, and pharmacologic studies using both mouse xenograft models and spontaneous acute canine leukemias demonstrate in vivo bioactivity as determined by functional assays and multiple biomarkers. Therefore, based on the collective preclinical data, we propose that the novel compound DMAPT has the potential to target human LSCs in vivo.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

LSC defenses breached by chemical arsenal
Tessa L. Holyoake and Mhairi Copland
Blood 2007 110: 4138-4139. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Toxicol SciHome page
G. Ramos, A. Y. Limon-Flores, and S. E. Ullrich
JP-8 Induces Immune Suppression via a Reactive Oxygen Species NF-{kappa}{beta}-Dependent Mechanism
Toxicol. Sci., March 1, 2009; 108(1): 100 - 109.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y.N. V. Gopal, E. Chanchorn, and M. W. Van Dyke
Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions
Mol. Cancer Ther., March 1, 2009; 8(3): 552 - 562.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. E. Dick
Stem cell concepts renew cancer research
Blood, December 15, 2008; 112(13): 4793 - 4807.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Hewamana, S. Alghazal, T. T. Lin, M. Clement, C. Jenkins, M. L. Guzman, C. T. Jordan, S. Neelakantan, P. A. Crooks, A. K. Burnett, et al.
The NF-{kappa}B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target
Blood, May 1, 2008; 111(9): 4681 - 4689.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Copland, F. Pellicano, L. Richmond, E. K. Allan, A. Hamilton, F. Y. Lee, R. Weinmann, and T. L. Holyoake
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors
Blood, March 1, 2008; 111(5): 2843 - 2853.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020